Assessment of γ-H2AX and 53BP1 Foci in Peripheral Blood Lymphocytes to Predict Subclinical Hematotoxicity and Response in Somatostatin Receptor-Targeted Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors.

Thorsten Derlin Natalia V BogdanovaFiona OhlendorfDhanya RamachandranRudolf A WernerTobias L RossHans ChristiansenFrank M BengelChristoph Henkenberens

Published in: Cancers (2021)

Assessment of γ-H2AX and 53BP1 foci formation in PBLs of patients receiving radioligand therapy may hold promise for predicting subclinical hematotoxicity and early treatment response.

Keyphrases

neuroendocrine tumors
peripheral blood
cancer therapy
stem cells
big data
mesenchymal stem cells
deep learning
cell therapy